Archives

More FDA answers to questions about cannabis-derived CBD drugs, foods, dietary supplements and food products including access to CBD for clinical investigations.

As more artificial intelligence products become available, the FDA is reevaluating its approval criteria. For now, De novo approval and 501(k) are being used along with premarket approval.

2:12 AM here and I had this dream. I went to an islander retreat site, the captain of the bus was telling me about the pandemic conditions. My son was there, but then the dream was about me. I [...]

In today’s video, we discuss the subject of corporate practice of medicine. Plenty of clients come to us having heard this very anachronistic term and ask us to help them understand what it means [...]

This is a community conversation session hosted by Cohen Healthcare Law Group – discussing Telemedicine: Potential Liability Pitfalls and Solutions in a COVID-19 World. We are joined today by our [...]

Federal Drug Administration continues to send warning letters to companies that boast products can treat, diagnose, prevent, or cure COVID-19 or boost immunity.

Physician recruitment agreements involve the rights and duties of three parties. Experienced healthcare lawyers craft the proper exceptions to the Anti-Kickback Statute and Stark Law

Federal Drug Administration has started sending warning letters to companies that boast their products can treat, diagnose, prevent, or cure COVID-19 or boost immunity.

In this video, we talk about some of the foundational legal documents you will need when you decide to implement a membership model for your medical practice or other healthcare clinical operation.

The Federal Trade Commission (FTC) announced the agency is sending warning letters to companies that claim its products can treat or prevent coronavirus (COVID-19) due to lack of scientific evidence